MetaCap

NextCure (NXTC) vs Serina Therapeutics (SER)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

NextCure (NXTC) has outperformed Serina Therapeutics (SER) over the past year, losing 38.6% versus a loss of 71.9%. Over five years, NXTC leads with a -91.1% price change compared with -95.6% for SER. Serina Therapeutics is the larger company by market cap ($29.8 million vs $29.5 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NXTC-38.63%SER-71.93%
+42%-25%-91%
Nov 21, 20251 yearNov 20, 2026
NXTC-90.73%SER-96.03%
+46%-29%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NXTC versus SER key metrics
MetricNXTCSER
Share price$6.45$1.12
Market cap$29.53M$29.76M
1-day change-4.87%-6.67%
YTD return-54.55%-41.45%
1-year return-38.63%-71.93%
5-year return-91.07%-95.64%
EPS (TTM)$-6.78$-1.63
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$130.00K
Revenue growth (YoY)—+132.14%
Net income (latest FY)$-55.84M$-19.18M
Operating margin—-18478.46%
Net margin—-14755.38%
52-week high$15.74$4.26
52-week low$1.55$1.06
Distance from 52-week high-59.02%-73.71%
Analyst consensusnonenone
Avg. price target upside+210.08%+748.21%
Average volume79.46K68.98K
Shares outstanding4.58M26.57M
Employees4016
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NXTC has outperformed SER by 33.3 percentage points over the past year.

About NextCure

NXTC stock →

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 40 employees

About Serina Therapeutics

SER stock →

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles.

Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees

NXTC vs SER FAQ

Which is bigger, NextCure or Serina Therapeutics?

Serina Therapeutics (SER) is larger, with a market capitalization of $29.76M compared with $29.53M for NextCure (NXTC).

Which stock has performed better over the past year, NXTC or SER?

NXTC returned -38.63% over the past 12 months, compared with -71.93% for SER (price return, excluding dividends). Past performance does not predict future results.

Are NextCure and Serina Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons